ArticleAmerican journal of nuclear medicine and molecular imaging2017
Diagnostic test accuracy study of
Article in American journal of nuclear medicine and molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Prognostic values of long noncoding RNA in bone metastasis of prostate cancer: A systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- The Role of Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Primary Staging of Newly Diagnosed Prostate Cancer: A Systematic Review of the Literature.European urology oncology · 2021Pooled it
- Comparison of PSMA-PET/CT, choline-PET/CT, NaF-PET/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis.Skeletal radiology · 2019Pooled it
- Progression-free Survival Following Primary Staging with [European urology open science · 2026Article
- Whole-Body SPECT/CT: Protocol Variation and Technical Consideration-A Narrative Review.Diagnostics (Basel, Switzerland) · 2024Review
- The potential advantages ofQuantitative imaging in medicine and surgery · 2024Article
- Comparison of the diagnostic value of 18F-NaF PET/CT andTranslational cancer research · 2023Review
- Quantitative vs. Qualitative SPECT-CT Diagnostic Accuracy in Bone Lesion Evaluation-A Review of the Literature.Diagnostics (Basel, Switzerland) · 2023Review
- Risk Evaluation of Bone Metastases and a Simple Tool for Detecting Bone Metastases in Prostate Cancer: A Population-Based Study.Computational and mathematical methods in medicine · 2023Article
- Comparison ofEuropean journal of hybrid imaging · 2022Article
- Comparison of Bone Metastases betweenContrast media & molecular imaging · 2022Article
- Article
- Comparison of PET/CT and MRI in the Diagnosis of Bone Metastasis in Prostate Cancer Patients: A Network Analysis of Diagnostic Studies.Frontiers in oncology · 2021Article
- Recent updates and developments in PET imaging of prostate cancer.Abdominal radiology (New York) · 2020Review
- Clinical value of dual-phase F-18 sodium fluoride PET/CT for diagnosing bone metastasis in cancer patients with solitary bone lesion.Quantitative imaging in medicine and surgery · 2020Article
- Article
- Added value ofEJNMMI research · 2020Article
- Observer Agreement and Accuracy ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020Article
- Imaging modalities in synchronous oligometastatic prostate cancer.World journal of urology · 2019Review
- Two decades of SPECT/CT - the coming of age of a technology: An updated review of literature evidence.European journal of nuclear medicine and molecular imaging · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to prospectively compare planar, bone scan (BS) versus SPECT/CT and NaF PET/CT in detecting bone metastases in prostate cancer. Thirty-seven consecutive, newly diagnosed, prostate cancer patients with prostate specific antigen (PSA) levels ≥ 50 ng/mL and who were considered eligible for androgen-deprivation therapy (ADT) were included in this study. BS, SPECT/CT, and NaF PET/CT, were performed prior to treatment and were repeated after six months of ADT. Baseline images from each index test were independently read by two experienced readers. The reference standard was based on a consensus decision made by a multidisciplinary team on the basis of baseline and follow-up images of the index tests, the findings of the baseline index tests by the experienced readers, and any available imaging, biochemical, and clinical data, including the response to ADT. Twenty-seven (73%) of the 37 patients had bone metastases according to the reference standard. The sensitivities for BS, SPECT/CT and NaF PET/CT were 78%, 89%, and 89%, respectively, and the specificities were 90%, 100%, and 90%, respectively. The positive predictive values of BS, SPECT/CT and NaF PET/CT were 96%, 100%, and 96%, respectively, and the negative predictive values were 60%, 77% and 75%, respectively. No statistically significant difference among the three imaging modalities was observed. All three imaging modalities showed high sensitivity and specificity. NaF PET/CT and SPECT/CT showed numerically improved, but not statistically superior, sensitivity compared with BS in this limited and selected patient cohort.
Indexed as
Identifiers
29181269PMC5698615What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.